Pharming revenue rises 21% to $117.6 million

Pharming Group (NASDAQ:PHAR) reported preliminary third-quarter 2026 revenue of $117.6 million, up 21% year over year, as operating profit rose 89% to $29.9 million.

Revenue growth exceeded the company's profit growth in absolute terms, with net profit reaching $22.4 million compared with $7.5 million in the third quarter of 2025.

Pharming said it narrowed its full-year 2026 revenue guidance to $380 million–$390 million from its previous range of $375 million–$395 million.

RUCONEST revenue increased 14% to $93.8 million, while Joenja revenue climbed 58% to $23.8 million.

The company also reported $5.1 million in manufacturing-related inventory impairments.

Joenja launched in Germany and Japan, and U.S. shipments of newly approved pediatric doses began in October, while cash, restricted cash and marketable securities totaled $190.9 million.

Pharming also reported that a Phase II leniolisib study in genetically identifiable immune disorders showed a mean spleen volume reduction of 26.4%, with broader common variable immunodeficiency results expected in November 2026.

The company expects enrollment in its FALCON trial to be completed in the first half of 2027, while its narrowed annual revenue guidance reflects its current outlook for the business.